LRMR
Larimar Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.83
+0.00%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-135.5%
Return on equity
-104.4%
Return on assets
-135.2%
Return on invested capital
0.00x
Asset turnover
-$155.9M
Cash from operations
$1.50
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026